Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
Abstract Objective To evaluate the magnitude, prevalence, and trend of the financial relationship between Japanese head and neck surgeons and pharmaceutical companies between 2016 and 2019. Study Design Cross‐sectional analysis. Setting Japan. Methods This study evaluated personal payments concernin...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | OTO Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/oto2.31 |
| _version_ | 1797537451243208704 |
|---|---|
| author | Anju Murayama Haruki Shigeta Sae Kamamoto Erika Yamashita Hiroaki Saito Toyoaki Sawano Divya Bhandari Sunil Shrestha Eiji Kusumi Tetsuya Tanimoto Akihiko Ozaki |
| author_facet | Anju Murayama Haruki Shigeta Sae Kamamoto Erika Yamashita Hiroaki Saito Toyoaki Sawano Divya Bhandari Sunil Shrestha Eiji Kusumi Tetsuya Tanimoto Akihiko Ozaki |
| author_sort | Anju Murayama |
| collection | DOAJ |
| description | Abstract Objective To evaluate the magnitude, prevalence, and trend of the financial relationship between Japanese head and neck surgeons and pharmaceutical companies between 2016 and 2019. Study Design Cross‐sectional analysis. Setting Japan. Methods This study evaluated personal payments concerning lecturing, consulting, and writing paid by 92 major pharmaceutical companies to all Japanese head and neck surgeons board‐certified by the Japan Society for Head and Neck Surgery between 2016 and 2019. The payments were descriptively analyzed and payment trend were assessed using population‐averaged generalized estimating equations. Further, the payments to board executive board members with specialist certification were also evaluated separately. Results Of all 443 board‐certified head and neck surgeons in Japan, 365 (82.4%) received an average of $6443 (standard deviation: $12,875), while median payments were $2002 (interquartile ranges [IQR] $792‐$4802). Executive board specialists with a voting right received much higher personal payments (median $26,013, IQR $12,747‐$35,750) than the non‐executive specialists (median $1926, IQR $765‒$4134, p < .001) and the executive board specialists without a voting right (median $4411, IQR $963‐$5623, p = .015). The payments per specialist and prevalence of specialists with payments annually increased by 11.4% (95% CI: 5.8%‐17.2%; p < .001) and 7.3% (95% CI: 3.8%‐11.0%; p < .001), respectively. Conclusion There were increasingly widespread and growing financial relationships with pharmaceutical companies among head and neck surgeons in Japan, alongside of introduction of novel drugs. The leading head and neck surgeons received much higher personal payments from pharmaceutical companies, and no sufficient regulation was implemented by the society in Japan. |
| first_indexed | 2024-03-10T12:16:18Z |
| format | Article |
| id | doaj.art-524358c6cd7d4bb5b6ef98f1f1a1329b |
| institution | Directory Open Access Journal |
| issn | 2473-974X |
| language | English |
| last_indexed | 2024-03-10T12:16:18Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | OTO Open |
| spelling | doaj.art-524358c6cd7d4bb5b6ef98f1f1a1329b2023-11-21T15:50:29ZengWileyOTO Open2473-974X2023-01-0171n/an/a10.1002/oto2.31Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019Anju Murayama0Haruki Shigeta1Sae Kamamoto2Erika Yamashita3Hiroaki Saito4Toyoaki Sawano5Divya Bhandari6Sunil Shrestha7Eiji Kusumi8Tetsuya Tanimoto9Akihiko Ozaki10Medical Governance Research Institute Minato‐ku Tokyo JapanMedical Governance Research Institute Minato‐ku Tokyo JapanMedical Governance Research Institute Minato‐ku Tokyo JapanMedical Governance Research Institute Minato‐ku Tokyo JapanMedical Governance Research Institute Minato‐ku Tokyo JapanDepartment of Surgery Jyoban Hospital of Tokiwa Foundation Iwaki City Fukushima JapanMedical Governance Research Institute Minato‐ku Tokyo JapanSchool of Pharmacy, Monash University Malaysia Jalan Lagoon Selatan Bandar Sunway Jalan Lagoon Selatan MalaysiaMedical Governance Research Institute Minato‐ku Tokyo JapanMedical Governance Research Institute Minato‐ku Tokyo JapanMedical Governance Research Institute Minato‐ku Tokyo JapanAbstract Objective To evaluate the magnitude, prevalence, and trend of the financial relationship between Japanese head and neck surgeons and pharmaceutical companies between 2016 and 2019. Study Design Cross‐sectional analysis. Setting Japan. Methods This study evaluated personal payments concerning lecturing, consulting, and writing paid by 92 major pharmaceutical companies to all Japanese head and neck surgeons board‐certified by the Japan Society for Head and Neck Surgery between 2016 and 2019. The payments were descriptively analyzed and payment trend were assessed using population‐averaged generalized estimating equations. Further, the payments to board executive board members with specialist certification were also evaluated separately. Results Of all 443 board‐certified head and neck surgeons in Japan, 365 (82.4%) received an average of $6443 (standard deviation: $12,875), while median payments were $2002 (interquartile ranges [IQR] $792‐$4802). Executive board specialists with a voting right received much higher personal payments (median $26,013, IQR $12,747‐$35,750) than the non‐executive specialists (median $1926, IQR $765‒$4134, p < .001) and the executive board specialists without a voting right (median $4411, IQR $963‐$5623, p = .015). The payments per specialist and prevalence of specialists with payments annually increased by 11.4% (95% CI: 5.8%‐17.2%; p < .001) and 7.3% (95% CI: 3.8%‐11.0%; p < .001), respectively. Conclusion There were increasingly widespread and growing financial relationships with pharmaceutical companies among head and neck surgeons in Japan, alongside of introduction of novel drugs. The leading head and neck surgeons received much higher personal payments from pharmaceutical companies, and no sufficient regulation was implemented by the society in Japan.https://doi.org/10.1002/oto2.31conflict of interesthead and neck cancerJapanpharmaceutical payment |
| spellingShingle | Anju Murayama Haruki Shigeta Sae Kamamoto Erika Yamashita Hiroaki Saito Toyoaki Sawano Divya Bhandari Sunil Shrestha Eiji Kusumi Tetsuya Tanimoto Akihiko Ozaki Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019 OTO Open conflict of interest head and neck cancer Japan pharmaceutical payment |
| title | Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019 |
| title_full | Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019 |
| title_fullStr | Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019 |
| title_full_unstemmed | Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019 |
| title_short | Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019 |
| title_sort | pharmaceutical payments to japanese board certified head and neck surgeons between 2016 and 2019 |
| topic | conflict of interest head and neck cancer Japan pharmaceutical payment |
| url | https://doi.org/10.1002/oto2.31 |
| work_keys_str_mv | AT anjumurayama pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT harukishigeta pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT saekamamoto pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT erikayamashita pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT hiroakisaito pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT toyoakisawano pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT divyabhandari pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT sunilshrestha pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT eijikusumi pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT tetsuyatanimoto pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 AT akihikoozaki pharmaceuticalpaymentstojapaneseboardcertifiedheadandnecksurgeonsbetween2016and2019 |